[ad_1]
The antiviral drug Remdesivir, approved by the US Food and Regulatory Agency, is expected. USA For emergency use to treat patients with COVID-19, it will be available next week, said the CEO of the company that makes the drug.
The announcement was made Sunday by Dan O’Day, CEO of
Gilead Sciences, the pharmaceutical company that makes the vaccine.
The United States is the most affected country in the world with more than
1.1 million cases of COVID-19 and more than 67,000 deaths, according to the Johns
Hopkins University data.
The Food and Drug Administration (FDA) gave emergency use
authorization (USA) for the use of Remdesivir in research to treat COVID-19
patients after some research, including one led by an American Indian doctor
Aruna Subramanian, discovered that the drug helped to recover some of the infected
Faster cases.
The EUA allows Remdesivir to be distributed in the US. USA
and administered intravenously by healthcare providers, as appropriate, to
treat suspected or laboratory-confirmed COVID-19 in adults and children
hospitalized with severe condition.
“We intend to bring that to patients in the first part of this
next week, “O’Day said on CBS” Face of the Nation. “
He said his company has donated all of its available products.
supply of Remdesivir, approximately 1.5 million vials, to the government, which
It can treat 100,000 to 200,000 people.
O’Day said the government “will determine which cities are
most vulnerable and where patients need this drug. “
Previously, the President of the United States, Donald Trump, said that his
the administration has been working with teams from the FDA, National Institute
of Health and Gilead for spearheading this public-private partnership to make
This happens very quickly.
In a statement, Gilead had previously said that the EUA
Facilitate the wider use of Remdesivir to treat hospitalized patients with
COVID-19 disease, which allows access to the vaccine in additional hospitals throughout
the country.
Remdesivir is authorized for the treatment of hospitalized patients.
patients with severe COVID-19 disease, he said, adding that the optimal
The duration of treatment is still being studied in ongoing clinical trials.
Under the USA, both five days and 10 days
The duration of treatment is suggested, depending on the severity of the disease. the
authorization is temporary and does not replace the new formal medicine
application filing, review and approval process, Gilead said.
[ad_2]
